Trial Profile
Phase II Study of Vx001 Vaccine in HLA-A*0201 Positive Patients With TERT Positive Stage IV or Recurrent Stage I-III NSCLC
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Vx 001 (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms VaxLung
- Sponsors Vaxon Biotech
- 25 Mar 2020 Primary endpoint (Time-to-event comparison of overall survival (OS) in Vx-001 treated vs placebo treated patients.) has not been met as per results published in the British Journal of Cancer
- 25 Mar 2020 Results published in the British Journal of Cancer
- 23 Jun 2017 This trial has been discontinued in Greece (end date: 5 Mar 2017).